• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Psyence Biomedical Ltd.

    4/20/26 8:25:16 AM ET
    $PBM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PBM alert in real time by email
    6-K 1 ea0286941-6k_psyence.htm REPORT OF FOREIGN PRIVATE ISSUER

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 6-K

     

    REPORT OF FOREIGN PRIVATE ISSUER

    PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE

    SECURITIES EXCHANGE ACT OF 1934

     

    For the month of April 2026

     

    Commission File Number: 001-41937

     

    PSYENCE BIOMEDICAL LTD.

    (Translation of registrant’s name into English)

     

    121 Richmond Street West

    Penthouse Suite 1300

    Toronto, Ontario M5H 2K1

    (Address of principal executive office)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

     

    ☒ Form 20-F ☐ Form 40-F

     

     

     

     

     

    EXPLANATORY NOTE

     

    On April 19, 2026, Psyence Biomedical Ltd. (the “Company”) entered into Amendment No. 3 to the Common Stock Purchase Agreement (the “Amendment”) with White Lion Capital, LLC (“White Lion”), amending the Common Stock Purchase Agreement dated July 25, 2024, as previously amended by Amendment No. 1 on December 20, 2024 and Amendment No. 2 on November 4, 2025 (as amended, the “Purchase Agreement”).

     

    The Amendment adds a new purchase mechanism to the Purchase Agreement pursuant to which the Company may, during the Commitment Period, deliver an “Intraday Purchase Notice” to White Lion, requiring White Lion to purchase a number of common shares of the Company (the “Common Shares”) not to exceed five percent (5%) of the Average Daily Trading Volume (the “Intraday Purchase Notice Limit”). Under the Intraday Purchase mechanism, White Lion must provide written consent to accept an Intraday Purchase Notice within 15 minutes of delivery; failure to do so will render the applicable notice void. The purchase price for shares sold pursuant to an Intraday Purchase Notice is the lowest traded price of the Common Shares during the one (1) hour period following White Lion’s written acceptance (the “Intraday Valuation Period”), subject to a floor price specified in the applicable notice. Settlement of any Intraday Purchase Notice will occur within two (2) Business Days of the applicable acceptance date, with White Lion delivering the applicable purchase amount by wire transfer of immediately available funds.

     

    The Amendment also amends and restates Section 5.1 of the Purchase Agreement to reflect the addition of the Intraday Purchase Notice mechanism, and amends the definition of “Purchase Notice” to include the new Intraday Purchase Notice Form (Exhibit G).

     

    In connection with the Amendment, White Lion has agreed to pay the Company a legal document preparation fee of $22,000 within two (2) Business Days of the Amendment effective date. Except as modified by the Amendment, the Purchase Agreement continues in full force and effect in accordance with its terms.

     

    The foregoing description of the Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the Amendment, which is filed as Exhibit 10.1 to this Report on Form 6-K and is incorporated herein by reference.

     

    1

     

    EXHIBIT INDEX

     

    Exhibit No.     Description
    10.1   Amendment No. 3 to Common Stock Purchase Agreement, dated April 19, 2026, by and between Psyence Biomedical Ltd. and White Lion Capital, LLC (filed herewith).

     

    2

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

    PSYENCE BIOMEDICAL LTD.  
       
    Dated: April 20, 2026  
       
    /s/ Jody Aufrichtig  
    Jody Aufrichtig  
    Chief Executive Officer and Director  

     

     

    3

     

     

    Get the next $PBM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PBM

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PBM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Psyence BioMed Positioned as World's only Licensed Pharmaceutical Grade Ibogaine Supplier at Source

    NEW YORK, April 20, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence BioMed" or the "Company"), a clinical-stage biopharmaceutical company advancing nature-derived psychedelic therapies and manufacturing pharmaceutical-grade drug candidates, today provided an update on its strategic position in the global ibogaine market, as regulatory and clinical interest in the compound continues to expand. Recent signals from U.S. policymakers and global health authorities reflect increasing recognition of the need for structured, evidence-based evaluation of ibogaine, particularly in areas where existing treatment options remain limited. In anticipation of this shift, Psyence B

    4/20/26 7:42:20 AM ET
    $PBM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Psyence BioMed Welcomes U.S. Executive Action to Advance Research into Ibogaine

    NEW YORK, April 17, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence BioMed" or the "Company"), a clinical-stage biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies, today acknowledged recent reports that the U.S. administration is preparing an executive order to further evaluate the safety and therapeutic potential of ibogaine, a naturally occurring compound being studied for its potential in treating post-traumatic stress disorder (PTSD), addiction, and other serious neurological and mental health conditions. The anticipated executive action reflects growing recognition of the need for rigorous, regulated research into novel therap

    4/17/26 9:15:00 AM ET
    $PBM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Psyence BioMed Expands Australian Clinical Site Network to Five Sites, Advancing NPX-5–Supported Clinical Activities

    NEW YORK, April 08, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence BioMed" or the "Company"), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today announced the expansion of its clinical site network in Australia from three to five sites supporting its ongoing clinical activities. The expansion includes the addition of Ramsay Health Care and NeuroCentrix, which enhances the Company's clinical network with experienced hospital and specialist research partners. The Company believes that their inclusion strengthens the Company's clinical program and enhances its ability to support ongoing clinical

    4/8/26 9:15:00 AM ET
    $PBM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PBM
    SEC Filings

    View All

    SEC Form 6-K filed by Psyence Biomedical Ltd.

    6-K - PSYENCE BIOMEDICAL LTD. (0001985062) (Filer)

    4/20/26 8:25:16 AM ET
    $PBM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Psyence Biomedical Ltd.

    6-K - PSYENCE BIOMEDICAL LTD. (0001985062) (Filer)

    4/17/26 4:59:56 PM ET
    $PBM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Psyence Biomedical Ltd.

    6-K - PSYENCE BIOMEDICAL LTD. (0001985062) (Filer)

    3/2/26 7:07:39 AM ET
    $PBM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PBM
    Leadership Updates

    Live Leadership Updates

    View All

    Corporate Update: Psyence BioMed Advances Vertically Integrated Pharmaceutical Platform Following PsyLabs Export Milestone

    NEW YORK, March 11, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence BioMed" or the "Company") today reinforced how its strategic investment in PsyLabs strengthens its control over pharmaceutical-grade manufacturing and commercial supply chain infrastructure – a critical differentiator in the rapidly expanding psychedelic pharmaceutical sector. Through its investment in PsyLabs, Psyence BioMed has secured: A licensed, owned, and debt-free production operation.Source-level ibogaine supply.Natural psilocybin supply.GMP-compliant manufacturing capabilities.Intellectual property protection.Integrated analytical and chemistry laboratory infrastructure.A capital structur

    3/11/26 9:15:00 AM ET
    $PBM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Psyence BioMed Announces Results of Annual and Special Meeting of Shareholders

    NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence BioMed" or the "Company"), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today announced the voting results from its Annual and Special Meeting of Shareholders (the "Meeting"), held at 9:00 a.m. Eastern Time on February 12, 2026. Shareholders voted in favour of all matters of business presented at the Meeting, including the election of directors, the appointment of auditors and the approval of share consolidation authority for the board of directors (the "Board"). All director nominees listed in the Company's management informat

    2/17/26 9:15:00 AM ET
    $PBM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Psyence BioMed Achieves Milestone in Natural Ibogaine HCl Production and Strengthens Balance Sheet With No Debt and $12m Cash

    NEW YORK, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence BioMed" or the "Company"), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today announced a significant scientific and manufacturing achievement. Through its investment in PsyLabs, Psyence BioMed has become the first Nasdaq-listed company to produce GMP-compliant, high-purity ibogaine hydrochloride (Ibogaine HCl) derived from a naturally extracted, ethically sourced supply in Africa. Ibogaine HCl is the purified, stabilised, crystalline salt form of ibogaine used in clinical and therapeutic settings and represents the standard ph

    1/5/26 9:15:00 AM ET
    $PBM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PBM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Psyence Biomedical Ltd.

    SC 13G - PSYENCE BIOMEDICAL LTD. (0001985062) (Subject)

    12/13/24 9:16:01 AM ET
    $PBM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Psyence Biomedical Ltd.

    SC 13G/A - PSYENCE BIOMEDICAL LTD. (0001985062) (Subject)

    12/9/24 1:36:43 PM ET
    $PBM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Psyence Biomedical Ltd.

    SC 13G/A - PSYENCE BIOMEDICAL LTD. (0001985062) (Subject)

    12/4/24 4:38:27 PM ET
    $PBM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PBM
    Financials

    Live finance-specific insights

    View All

    From Super Fibers to Super Deals: Science, Scale, and Strategic Capital Shape the Morning Tape

    DENVER, Dec. 19, 2025 (GLOBE NEWSWIRE) -- This morning's market narrative spans futuristic materials, transformational biotech M&A, and creative capital restructuring, underscoring how innovation-driven companies are pairing long-term vision with near-term execution. Kraig Biocraft Laboratories, Inc. (OTCQB:KBLB): Spider Silk Moves From Legend to Industrial Reality Kraig Biocraft Laboratories set a distinctive tone with a detailed Christmas shareholder letter that framed 2025 as the company's inflection year, marking its transition from prolonged development into early commercialization of recombinant spider silk. The operational message was concrete, as Kraig Labs highlighted major adv

    12/19/25 9:48:44 AM ET
    $FOLD
    $PBM
    $PRPH
    Biotechnology: Pharmaceutical Preparations
    Health Care